Uses of orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation.
We have shown that OKT3 can be safely administered to a varied group of transplant recipients, including a high percentage of diabetics and older patients. Used as a prophylactic agent, OKT3 was associated with a decreased incidence and delayed onset of acute rejection. Effectiveness may be reduced by shortening the course of treatment and/or lowering the dose of concomitant azathioprine. Use of OKT3 in patients with ATN (thereby avoiding use of CyA) may be a beneficial strategy. Stimulation of significant titers of antimurine antibody has not been a common event in this study.
Kahana
L
L
Department of Internal Medicine, University of South Florida, Tampa.
Ackermann
J
J
Lefor
W
W
Weinstein
S
S
Wright
C
C
DeQuesada
A
A
Alveranga
D
D
Baxter
J
J
Shires
D
D
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003141:Communicable Diseases / Q000209:etiology; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3; D011897:Random Allocation
D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3; D003404:Creatinine